Latest Breaking News On - Christos kyriakopoulos - Page 1 : comparemela.com

Revisit Every OncLive On Air Episode from March 2024

In case you missed any, below is a recap of every episode of OncLive On Air that aired in March 2024.

United statesNorth carolinaMargot oneillArvindn dasariD ross camidgeMichael leungJohnh stricklerAlex herreraLos angelesZeva wainbergStephen bagleyAndrewj wagnerMarka lewisMatthew lunningHarvard medical schoolUniversity of nebraska medical center

ESSA Pharma Presents Updated Phase 1 Masofaniten (EPI-7386) Clinical Data at the 2024 ASCO Genitourinary Cancers Symposium

ESSA Pharma Presents Updated Phase 1 Masofaniten (EPI-7386) Clinical Data at the 2024 ASCO Genitourinary Cancers Symposium
urotoday.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from urotoday.com Daily Mail and Mail on Sunday newspapers.

San franciscoUnited statesDavid parkinsonUniversity of wisconsinPharma incMadison carbone cancer centerCancers symposiumChristos kyriakopoulosWisconsin madison carbone cancer

Dr Kyriakopoulos on the Initial Activity and Safety of Masofaniten Plus Enzalutamide in mCRPC

Christos Kyriakopoulos, MD, discusses data from a phase 1/2 study of masofaniten plus enzalutamide in metastatic castration-resistant prostate cancer.

United statesUniversity of wisconsin school medicinePublic healthDepartment of medicineDivision of hematologyChristos kyriakopoulosMedical oncologyPalliative careWisconsin schoolCancers symposiumProstate cancerAsco gu

ESSA Pharma (EPIX) Presents Updated Phase 1 Masofaniten Data

ESSA Pharma (EPIX) Presents Updated Phase 1 Masofaniten Data
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

San franciscoUnited statesDavid parkinsonEssa pharma incMadison carbone cancer centerUniversity of wisconsinCancers symposiumChristos kyriakopoulosWisconsin madison carbone cancer

ESSA Pharma Presents Updated Phase 1 Masofaniten (EPI-7386) Clinical Data at the 2024 ASCO Genitourinary Cancers Symposium

Combination of masofaniten plus enzalutamide continues to be well tolerated with deep and durable reductions in PSA in patients with mCRPC Phase 2 dose expansion currently underway at the RP2CDs of.

United statesSan franciscoBritish columbiaPeter virsikDavid parkinsonDrug administrationPharma incMadison carbone cancer centerUniversity of wisconsinCancers symposiumChristos kyriakopoulosWisconsin madison carbone cancerFast trackPrivate securities litigation reform actChief operating